Side Branch Stenting Using Sirolimus-Eluting Stents in Bifurcation Lesions Trial Presented at The American College of Cardiology Scientific Session 2006.

Slides:



Advertisements
Similar presentations
Paclitaxel-eluting Stents vs Brachytherapy for In-stent Restenosis (TAXUS V ISR) Trial Presented at The American College of Cardiology Scientific Session.
Advertisements

Intracoronary Autologous Bone-Marrow Cell Transfer after Myocardial Infarction: A Double-Blind, Randomized, and Placebo-Controlled Clinical Trial Presented.
BBC ONE David Hildick-Smith Sussex Cardiac Centre Brighton, UK on behalf of the BBC ONE Investigators.
Www. Clinical trial results.org  Major Endpoints: Death, MI, stent thrombosis, TLR, TVR, MACE, and CKMB >3x nl  Major Endpoints: Death, MI, stent thrombosis,
BIFURCATION LESIONS Dr. Tahsin.N
Radial versus Femoral Randomized Investigation in ST Elevation Acute Coronary Syndrome the RIFLE STEACS study Enrico Romagnoli, MD PhD Principal investigators:
Glucose – Insulin – Potassium Study in Patients with ST Elevation Myocardial Infarction without Signs of Heart Failure Presented at American College of.
29th ANNUAL SCIENTIFIC SESSIONS – SCA&I
Treating to New Targets Study TNT Trial Presented at The American College of Cardiology Scientific Sessions 2005 Presented by Dr. John C. LaRosa.
Randomized Angioplasty Beta Blocker Intracoronary Trial II (RABBIT II) Presented at The American Heart Association Scientific Session 2006 Presented by.
Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE) Trial Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE)
The AiMI Trial Arshad Ali, MD, David Cox, MD, Nabil Dib, MD, Bruce Brodie, MD, Daniel Berman, MD, Navin Gupta, MD, Kevin Browne, MD, Robert Iwaoka, MD,
Drug-Eluting Stent Mortality Meta-Analysis Presented at European Society of Cardiology Scientific Congress, September 2006 Presented by Dr. Alain J. Nordmann.
Francesco Liistro Cardiovascular Department, Arezzo, Italy Impact of Thrombus Aspiration on Myocardial Tissue Reperfusion and Left Ventricular Functional.
Value of Endothelin Receptor Inhibition with Tezosentan in Acute Heart Failure Studies VERITAS Trial Presented at The American College of Cardiology Scientific.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
Effects of PG , a Matrix Metalloproteinase Inhibitor to Prevent Left Ventricular Remodeling After Acute Myocardial Infarction Effects of PG ,
BURZOTTA F. 1, PAN M. 2 (CO-FIRST AUTHOR), TRANI C. 1, MEDINA A. 3, SUÀREZ DE LEZO J. 2, NICCOLI G. 1, ROMERO M. 2, PORTO I. 1, MAZUELOS F. 2, LEONE A.M.
Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) Trial IDEAL Trial Presented at The American Heart Association Scientific.
Limbs International Medical Buflomedil Trial Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Alain Leizorovicz LIMB.
Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty Study (ARMYDA-2) Trial ARMYDA-2 Trial Presented at The American College of Cardiology.
Arterial Revascularization Therapies Part II: a non- randomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with.
Rapamycin- and Paclitaxel-Eluting Stents With Identical Biodegradable Polymeric Coating and Design Trial Presented at The American College of Cardiology.
Occluded Artery Trial (OAT) Presented at The American Heart Association Scientific Session 2006 Presented by Dr. Judith S. Hochman OAT Trial.
Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons Presented at The American Heart Association Scientific Session 2006 Presented by Dr.
Rescue Angioplasty versus Conservative Therapy or Repeat Thrombolysis Trial Presented at American Heart Association Scientific Sessions 2004 Presented.
Safety and Efficacy of Intravenous Enoxaparin in Elective Percutaneous Coronary Intervention: an International Randomized Evaluation (STEEPLE) Presented.
Norwegian Vitamin Trial NORVITNORVIT Presented at The European Society of Cardiology Congress 2005 Presented by Dr. Kaare Harold Bønaa.
The Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction (ASSENT-4 PCI) Trial ASSENT- 4 PCI Trial Presented.
Basel Stent Cost-Effectiveness (BASKET) Trial BASKET Trial Presented at The European Society of Cardiology Hotline Session 2005 Presented by Dr. Matthias.
Atorvastatin for Reduction of Myocardial Dysrhythmias After Cardiac Surgery Trial Presented at The American College of Cardiology Scientific Sessions March.
Tirofiban and Sirolimus-Eluting Stent vs Abciximab and Bare-Metal Stent for Acute Myocardial Infarction STRATEGY Trial Journal of the American Medical.
Paclitaxel Eluting Stent Versus Conventional Stent in ST-segment Elevation Myocardial Infarction (PASSION) Trial Presented at The American College of Cardiology.
Slow-rate release polymer-based paclitaxel- eluting stent compared with bare stent in patients with single complex coronary lesions TAXUS V Presented at.
Harmonizing Outcomes with RevascularIZatiON and Stents (HORIZONS) Trial HORIZONS Trial.
Treatment of bifurcation lesions is a complex problem Different techniques are commonly used (Y-/T-stenting, „culotte“ technique, „kissing stent“ technique…)
Perindopril Remodeling in Elderly with Acute Myocardial Infarction PREAMIPREAMI Presented at The European Society of Cardiology Hot Line Session, September.
Www. Clinical trial results.org Cypher sirolimus-eluting stent Primary Endpoint:  In-stent and late lumen loss at 9 months (determined by QCA) Secondary.
TLR Funnel plot (according to outcomes) for studies included in the meta-analysis Death A TVR B MACE DC SE(log OR)
Prospective Evaluation of EECP in Congestive Heart Failure (PEECH) Trial PEECH Trial Presented at The American College of Cardiology Scientific Sessions.
European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.
Organization for the Assessment of Strategies for Ischemic Syndromes 6 (OASIS-6) Trial Presented at The American College of Cardiology Scientific Session.
Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.
Cardioprotective Effects of Postconditioning in Patients Treated with Primary PCI Evaluated with Magnetic Resonance Jacob T Lønborg Niels Vejlstrup, Erik.
RAVEL 4 YEAR FOLLOW-UP - Cordis Cardiology / Cardialysis – Euro-PCR – Sousa – 24 May 2005 RAVEL A RAndomised, double-blind study with the Sirolimus-eluting.
Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction (ASSENT-4 PCI) Trial ASSENT- 4 PCI Trial Presented at.
Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at The American College.
The American College of Cardiology Presented by Dr. Adnan Kastrati
The American College of Cardiology Presented by Dr. Adnan Kastrati
The European Society of Cardiology Presented by Dr. Bo Lagerqvist
FINAL FIVE-YEAR CLINICAL OUTCOMES OF THE NOBORI2 TRIAL
Stenting of Coronary Arteries in Non Stress/Benestent Disease
Presented by Dr. Leif Thuesen
Giuseppe Biondi Zoccai
The American College of Cardiology Presented by Dr. Maurits T. Dirksen
American College of Cardiology Presented by Dr. Stephan Windecker
REALITY: 8 month results
The American College of Cardiology Presented by Dr. Raimund Erbel
American Heart Association Presented by Dr. Julinda Mehilli
Main branch restenosis at 1 year
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
Role of Stenting in Acute MI: PAMI Stent Pilot Trial
The American College of Cardiology Presented by Dr. Timothy Henry
ARISE Trial Aggressive Reduction of Inflammation Stops Events
SMART-STRATEGY Trial design: Patients with a bifurcation coronary lesion were randomized to a conservative strategy (n = 128) vs. an aggressive strategy.
Presented at TCT 2006.
Chest Pain Choice Trial design: Patients presenting to the ED with low risk chest pain were randomized to either use of a tailored decision aid or routine.
Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial
The American College of Cardiology Presented by Dr. A. Abazid
TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.
Presentation transcript:

Side Branch Stenting Using Sirolimus-Eluting Stents in Bifurcation Lesions Trial Presented at The American College of Cardiology Scientific Session 2006 Presented by Dr. Terje K. Steigen Side Branch Stenting Using Sirolimus-Eluting Stents in Bifurcation Lesions Trial

www. Clinical trial results.org This study sought to determine whether side branch stenting using sirolimus-eluting stents could offer any advantage in the stenting of bifurcation lesions in patients with angina pectoris.This study sought to determine whether side branch stenting using sirolimus-eluting stents could offer any advantage in the stenting of bifurcation lesions in patients with angina pectoris. Presented at ACC 2006 Side Branch Stenting Using SES in Bifurcation Lesions Trial: Background

www. Clinical trial results.org Side Branch Stenting Using SES in Bifurcation Lesions Trial: Study Design  Primary Endpoint: Major adverse cardiac event (MACE) at 6 months, defined as cardiac death, myocardial infarction (MI), target lesion revascularization (TLR) or stent thrombosis of index lesion. Stenting of the main vessel and side branch (MV+SB) and side branch (MV+SB)n=206 If TIMI Flow Grade was <3 following main vessel stenting, the side branch was dilated If TIMI Flow Grade was <3 following main vessel stenting, the side branch was dilated If after dilation the TIMI Flow Grade was 0, the side branch was then stented If after dilation the TIMI Flow Grade was 0, the side branch was then stented Stenting of the main vessel and side branch (MV+SB) and side branch (MV+SB)n=206 If TIMI Flow Grade was <3 following main vessel stenting, the side branch was dilated If TIMI Flow Grade was <3 following main vessel stenting, the side branch was dilated If after dilation the TIMI Flow Grade was 0, the side branch was then stented If after dilation the TIMI Flow Grade was 0, the side branch was then stented Stenting of the main vessel and optional stenting of the side branch (MV) n=207 n= patients presenting with angina pectoris and a bifurcation lesion Randomized. 22% female, mean age 64 years, mean follow-up 6 months 413 patients presenting with angina pectoris and a bifurcation lesion Randomized. 22% female, mean age 64 years, mean follow-up 6 months Presented at ACC 2006

www. Clinical trial results.org Stenting of the side branch was performed in 95.1% of the MV+SB group and 4.3% of the MV groupStenting of the side branch was performed in 95.1% of the MV+SB group and 4.3% of the MV group GP IIb/IIIa inhibitors were used in 51% of the patientsGP IIb/IIIa inhibitors were used in 51% of the patients Presented at ACC 2006 Side Branch Stenting Using SES in Bifurcation Lesions Trial: Background Data

www. Clinical trial results.org Biomarker elevation was more common in the MV+SB groupBiomarker elevation was more common in the MV+SB group Presented at ACC 2006 Side Branch Stenting Using SES in Bifurcation Lesions Trial: Procedural Outcomes p=0.008 p=0.011 Biomarker Elevation at 6 months (%)

www. Clinical trial results.org The duration of the procedure and fluoroscopy time were increased in the MV+SB group, as well as the use of contrast.The duration of the procedure and fluoroscopy time were increased in the MV+SB group, as well as the use of contrast. Presented at ACC 2006 Side Branch Stenting Using SES in Bifurcation Lesions Trial: Procedural Outcomes Time (minutes) Volume (mL) Procedure and Fluoroscopy Duration (min) p<0.001 Vol. of Contrast Administered (mL) p<0.001

www. Clinical trial results.org Side Branch Stenting Using SES in Bifurcation Lesions Trial: Primary Endpoint Primary Endpoint of MACE at 6 months (%) p=NS Presented at ACC 2006 There was no difference in major adverse cardiac events at 6 months (4.4% vs 3.4%; p=NS).There was no difference in major adverse cardiac events at 6 months (4.4% vs 3.4%; p=NS).

www. Clinical trial results.org There was no difference in six month cardiac death (1.0% each).There was no difference in six month cardiac death (1.0% each). There was no significant difference in clinical MI (1.0% vs 1.4%) or target lesion revascularization (2.0% vs 1.4%).There was no significant difference in clinical MI (1.0% vs 1.4%) or target lesion revascularization (2.0% vs 1.4%). Components of the Primary Endpoint (%) p=NS Presented at ACC 2006 Side Branch Stenting Using SES in Bifurcation Lesions Trial: Primary Endpoint Components

www. Clinical trial results.org Procedure related MI was defined as a five- fold elevation of biochemical markers.Procedure related MI was defined as a five- fold elevation of biochemical markers. Procedure related MI occurred more than three times as often in the MV+SB group (13% vs 4%; p=0.008).Procedure related MI occurred more than three times as often in the MV+SB group (13% vs 4%; p=0.008). Procedure Related Myocardial Infarction (%) p=0.008 Presented at ACC 2006 Side Branch Stenting Using SES in Bifurcation Lesions Trial: Procedure Related MI

www. Clinical trial results.org There was no significant difference in stent thrombosis between the two groups (0% vs 1.0%; p=NS).There was no significant difference in stent thrombosis between the two groups (0% vs 1.0%; p=NS). Stent Thrombosis (%) p=NS Presented at ACC 2006 Side Branch Stenting Using SES in Bifurcation Lesions Trial: Stent Thrombosis

www. Clinical trial results.org Treatment success was similar in both groups (95% vs 97%; p=NS).Treatment success was similar in both groups (95% vs 97%; p=NS). Treatment Success (%) p=NS Presented at ACC 2006 Side Branch Stenting Using SES in Bifurcation Lesions Trial: Treatment Success

www. Clinical trial results.org Side Branch Stenting Using SES in Bifurcation Lesions Trial: Limitations A future study might include/exclude patients based on lesion location to allow for a more controlled patient population. The present trial stented bifurcation lesions in the Left Main, LAD, LCx, and RCA.A future study might include/exclude patients based on lesion location to allow for a more controlled patient population. The present trial stented bifurcation lesions in the Left Main, LAD, LCx, and RCA. Presented at ACC 2006

www. Clinical trial results.org Side Branch Stenting Using SES in Bifurcation Lesions Trial: Summary Among patients with angina pectoris and a bifurcation lesion, stenting of the main vessel and side branch was associated with no difference in MACE at six months but an increase in peri-procedural MI compared with a strategy of stenting of the main vessel and optional stenting of side branch.Among patients with angina pectoris and a bifurcation lesion, stenting of the main vessel and side branch was associated with no difference in MACE at six months but an increase in peri-procedural MI compared with a strategy of stenting of the main vessel and optional stenting of side branch. Given the lack of clinical benefit and the increase in peri- procedural MI, side-branch stenting of bifurcation lesions does not appear to be a valid treatment strategy.Given the lack of clinical benefit and the increase in peri- procedural MI, side-branch stenting of bifurcation lesions does not appear to be a valid treatment strategy. Among patients with angina pectoris and a bifurcation lesion, stenting of the main vessel and side branch was associated with no difference in MACE at six months but an increase in peri-procedural MI compared with a strategy of stenting of the main vessel and optional stenting of side branch.Among patients with angina pectoris and a bifurcation lesion, stenting of the main vessel and side branch was associated with no difference in MACE at six months but an increase in peri-procedural MI compared with a strategy of stenting of the main vessel and optional stenting of side branch. Given the lack of clinical benefit and the increase in peri- procedural MI, side-branch stenting of bifurcation lesions does not appear to be a valid treatment strategy.Given the lack of clinical benefit and the increase in peri- procedural MI, side-branch stenting of bifurcation lesions does not appear to be a valid treatment strategy. Presented at ACC 2006